SLC5A2 and diabetes mellitus: A similar proportion of people were treated with insulin (62% vs 58%) and oral anti-diabetes agents including SGLT2 inhibitors, with fewer patients in the BMI ≥ 35 kg/m2 group on sulphonylureas (31% vs 39%) (Fig. 2).